We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medical device major Integra LifeSciences Holdings Corporation’s (IART - Free Report) premier shoulder arthroplasty portfolio is expected to get a major boost with the company’s recent launch of the Integra Fin-Lock Glenoid. This being an addition to the company’s Titan Modular Shoulder System will increase glenoid offerings that will help maximize long-term fixation and implant longevity.
We note that the prime cause related to the complications and failure in total shoulder arthroplasty is Glenoid component loosening. However, the Fin-Lock Glenoid by Integra has a specific design that addresses this problem, providing immediate and enduring stability. Apart from the advanced design of this prosthesis, it is made of highly crosslinked polyethylene that improves wear characteristics of the implant.
Integra is currently running its business per a three-pillar strategy − optimize, execute and accelerate growth. According to management, these three pillars support the company’s strategic initiatives to optimize its infrastructure, deliver its commitments through improved planning and communication, and grow by introducing new products through internal development, geographic expansion and strategic acquisitions.
Integra has adopted several near-term objectives to align with its three-pillar strategy, one of which is investments in innovative product development, which should result in a multi-generational pipeline for the company’s key products. For 2016, the company is currently working on the integration of Salto ankle, which is expected to be completed soon and subsequently generate growth later this year. Integra has also begun controlled market release of the Cadence Total Ankle System − its internally developed two-piece ankle. The company expects Cadence to complement Salto’s proven clinical history and revision feature.
Apart from the latest released Fin-Lock Glenoid, management also expects to gain market share with some new product introductions in Integra’s Extremities franchise, such as X-Fix – the new external fixation product, and a new version of Panta – Integra’s leadership product for internal fixation.
Currently, Integra carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the same sector are ANI Pharmaceuticals, Inc. (ANIP - Free Report) , Heska Corporation and Neogenomics Inc. (NEO - Free Report) . All the three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Integra Unveils Fin-Lock Glenoid, Boosts Shoulder Arthroplasty
Medical device major Integra LifeSciences Holdings Corporation’s (IART - Free Report) premier shoulder arthroplasty portfolio is expected to get a major boost with the company’s recent launch of the Integra Fin-Lock Glenoid. This being an addition to the company’s Titan Modular Shoulder System will increase glenoid offerings that will help maximize long-term fixation and implant longevity.
We note that the prime cause related to the complications and failure in total shoulder arthroplasty is Glenoid component loosening. However, the Fin-Lock Glenoid by Integra has a specific design that addresses this problem, providing immediate and enduring stability. Apart from the advanced design of this prosthesis, it is made of highly crosslinked polyethylene that improves wear characteristics of the implant.
Integra is currently running its business per a three-pillar strategy − optimize, execute and accelerate growth. According to management, these three pillars support the company’s strategic initiatives to optimize its infrastructure, deliver its commitments through improved planning and communication, and grow by introducing new products through internal development, geographic expansion and strategic acquisitions.
Integra has adopted several near-term objectives to align with its three-pillar strategy, one of which is investments in innovative product development, which should result in a multi-generational pipeline for the company’s key products. For 2016, the company is currently working on the integration of Salto ankle, which is expected to be completed soon and subsequently generate growth later this year. Integra has also begun controlled market release of the Cadence Total Ankle System − its internally developed two-piece ankle. The company expects Cadence to complement Salto’s proven clinical history and revision feature.
Apart from the latest released Fin-Lock Glenoid, management also expects to gain market share with some new product introductions in Integra’s Extremities franchise, such as X-Fix – the new external fixation product, and a new version of Panta – Integra’s leadership product for internal fixation.
Currently, Integra carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the same sector are ANI Pharmaceuticals, Inc. (ANIP - Free Report) , Heska Corporation and Neogenomics Inc. (NEO - Free Report) . All the three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>